Martin Bitzan

4.3k total citations
84 papers, 2.4k citations indexed

About

Martin Bitzan is a scholar working on Endocrinology, Nephrology and Infectious Diseases. According to data from OpenAlex, Martin Bitzan has authored 84 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Endocrinology, 27 papers in Nephrology and 23 papers in Infectious Diseases. Recurrent topics in Martin Bitzan's work include Escherichia coli research studies (26 papers), Renal Diseases and Glomerulopathies (23 papers) and Viral gastroenteritis research and epidemiology (19 papers). Martin Bitzan is often cited by papers focused on Escherichia coli research studies (26 papers), Renal Diseases and Glomerulopathies (23 papers) and Viral gastroenteritis research and epidemiology (19 papers). Martin Bitzan collaborates with scholars based in Canada, United States and Germany. Martin Bitzan's co-authors include Helge Karch, Kerstin U. Ludwig, Martina Bielaszewska, Herbert Schmidt, Paul Goodyer, Dirk E. Müller‐Wiefel, D. E. Müller‐Wiefel, Holger Rüssmann, Florian Gunzer and H. Böhm and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Martin Bitzan

77 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin Bitzan Canada 28 1.2k 947 671 637 282 84 2.4k
Lothar Bernd Zimmerhackl Germany 30 816 0.7× 729 0.8× 887 1.3× 613 1.0× 378 1.3× 90 3.4k
Richard L. Siegler United States 27 1.1k 1.0× 769 0.8× 1.1k 1.6× 325 0.5× 497 1.8× 96 2.7k
Nicole C. A. J. van de Kar Netherlands 31 611 0.5× 463 0.5× 1.6k 2.4× 1.1k 1.7× 240 0.9× 118 2.7k
Margaret M. Fitzpatrick United Kingdom 13 255 0.2× 143 0.2× 297 0.4× 242 0.4× 170 0.6× 26 947
Dat P. Mao United States 8 230 0.2× 175 0.2× 1.2k 1.7× 180 0.3× 1.9k 6.6× 8 2.4k
Monica Dors United States 3 251 0.2× 172 0.2× 1.2k 1.7× 150 0.2× 1.7k 6.0× 3 2.2k
Brian P. Butler United States 17 436 0.4× 570 0.6× 308 0.5× 26 0.0× 1.2k 4.4× 29 2.5k
Milan Chromek Sweden 18 318 0.3× 150 0.2× 362 0.5× 84 0.1× 499 1.8× 35 1.6k
Richard L. Myerowitz United States 25 595 0.5× 557 0.6× 270 0.4× 17 0.0× 490 1.7× 52 2.4k
James K. Roche United States 30 113 0.1× 456 0.5× 475 0.7× 25 0.0× 424 1.5× 64 2.2k

Countries citing papers authored by Martin Bitzan

Since Specialization
Citations

This map shows the geographic impact of Martin Bitzan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Bitzan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Bitzan more than expected).

Fields of papers citing papers by Martin Bitzan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Bitzan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Bitzan. The network helps show where Martin Bitzan may publish in the future.

Co-authorship network of co-authors of Martin Bitzan

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Bitzan. A scholar is included among the top collaborators of Martin Bitzan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Bitzan. Martin Bitzan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Šimková, Eva, et al.. (2024). 365.11: Pediatric kidney transplantation in Dubai. Outcomes and challenges.. Transplantation. 108(9S).
2.
Al-Aubodah, Tho-Alfakar, Lamine Aoudjit, David Langlais, et al.. (2023). The extrafollicular B cell response is a hallmark of childhood idiopathic nephrotic syndrome. Nature Communications. 14(1). 7682–7682. 13 indexed citations
3.
Herlitz, Leal, Eva Šimková, Alan Taylor, et al.. (2020). Case Report: CMV-Associated Congenital Nephrotic Syndrome. Frontiers in Pediatrics. 8. 580178–580178. 6 indexed citations
4.
Samuel, Susan, Guido Filler, Martin Bitzan, et al.. (2019). The Canadian childhood nephrotic syndrome (CHILDNEPH) study: report on mid-study feasibility, recruitment and main measures. BMC Nephrology. 20(1). 3 indexed citations
5.
Bitzan, Martin, et al.. (2018). Complement depletion and Coombs positivity in pneumococcal hemolytic uremic syndrome (pnHUS). Case series and plea to revisit an old pathogenetic concept. International Journal of Medical Microbiology. 308(8). 1096–1104. 12 indexed citations
6.
Bitzan, Martin, et al.. (2017). Rituximab in Minimal Change Disease. Canadian Journal of Kidney Health and Disease. 4. 2245577835–2245577835. 15 indexed citations
7.
Bitzan, Martin & Jakub Zieg. (2017). Influenza-associated thrombotic microangiopathies. Pediatric Nephrology. 33(11). 2009–2025. 40 indexed citations
8.
Bitzan, Martin, Paul Goodyer, Thomas M. Kitzler, et al.. (2015). Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis. American Journal of Physiology-Renal Physiology. 310(10). F1148–F1156. 26 indexed citations
9.
Gupta, Indra R., Cindy Baldwin, Kevin Ha, et al.. (2013). ARHGDIA : a novel gene implicated in nephrotic syndrome. Journal of Medical Genetics. 50(5). 330–338. 66 indexed citations
10.
Bitzan, Martin, et al.. (2010). Treatment of Typical (Enteropathic) Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis. 36(6). 594–610. 42 indexed citations
11.
Bitzan, Martin, et al.. (2009). Rituximab (B‐cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature. Pediatric Pulmonology. 44(9). 922–934. 44 indexed citations
12.
Wilson, Cornelia M., Gregory H. Foster, & Martin Bitzan. (2005). Silencing of Bak Ameliorates Apoptosis of Human Proximal Tubular Epithelial Cells by Escherichia coli–Derived Shiga Toxin 2. Infection. 33(5-6). 362–367. 15 indexed citations
13.
Bitzan, Martin, et al.. (2004). Verotoxin (Shiga Toxin) Sensitizes Renal Epithelial Cells to Increased Heme Toxicity. Journal of the American Society of Nephrology. 15(9). 2334–2343. 26 indexed citations
14.
Bitzan, Martin & Helge Karch. (2003). Serological Methods for the Detection of STEC Infections. Humana Press eBooks. 73. 27–44. 2 indexed citations
15.
Ludwig, Kerstin U., Martin Bitzan, Christoph Bobrowski, & Dirk E. Müller‐Wiefel. (2002). Escherichia coliO157 Fails to Induce a Long‐Lasting Lipopolysaccharide‐Specific, Measurable Humoral Immune Response in Children with Hemolytic‐Uremic Syndrome. The Journal of Infectious Diseases. 186(4). 566–569. 20 indexed citations
16.
Bitzan, Martin, B. D. Gold, Dana J. Philpott, et al.. (1998). Inhibition of Helicobacter pylori and Helicobacter mustelae Binding to Lipid Receptors by Bovine Colostrum. The Journal of Infectious Diseases. 177(4). 955–961. 41 indexed citations
17.
Ludwig, Kerstin U., H. Ruder, Martin Bitzan, Stefan Zimmermann, & Helge Karch. (1997). Outbreak ofEscherichia coli O157:H7 infection in a large family. European Journal of Clinical Microbiology & Infectious Diseases. 16(3). 238–241. 14 indexed citations
18.
19.
Bitzan, Martin, et al.. (1991). High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome. The Journal of Pediatrics. 119(3). 380–385. 114 indexed citations
20.
Ulmer, Hans Ulrich, et al.. (1990). Schwangerschaften nach Organtransplantation*. Geburtshilfe und Frauenheilkunde. 50(10). 798–805. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026